Glenmark Pharmaceuticals Inc., USA Launches Olanzapine for Injection
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the official launch of Olanzapine for Injection, 10mg/vial, available as a Single-Dose Vial.
The newly launched product is bioequivalent...
GSK-partnered Hansoh Pharma reports positive Phase III lung cancer data.
GSK plc shared an announcement from its licensor, HansohPharmaceutical Group Co., Ltd., confirming that the pivotal phase III ARTEMIS-008 trial evaluating risvutatug rezetecan(Ris-Rez) met its primary endpoint...
FDA Grants Accelerated Approval to Vera Therapeutics’ TRUTAKNA™️ for Primary IgA Nephropathy
Vera Therapeutics, Inc. (Nasdaq: VERA) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TRUTAKNA™ (atacicept-vymj). The therapy is...
Enhertu Becomes First HER2 Tumour-Agnostic Therapy Approved in Europe for solid tumours
AstraZeneca and Daiichi Sankyo announced that the European Commission has approved Enhertu (trastuzumab deruxtecan) as a monotherapy for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours...
Alembic Pharmaceuticals receives final USFDA approval for Dapsone Gel, 5%for topical treatment of acne vulgaris
Alembic Pharmaceuticals Limited has secured final regulatory clearance from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for...
Viatris’ VR-205 Shows Strong Phase 3 Results in Japanese IgA Nephropathy Patients
Viatris Inc. (Nasdaq: VTRS) - reported encouraging top-line data from a Phase 3 trial of VR-205, a targeted-release budesonide therapy marketed elsewhere as Tarpeyo and Kinpeygo, in Japanese adults living...